We have succeeded in treating intractable autoimmune diseases in chimeric resistant MRL/lpr mice by a new bone marrow transplantation (BMT) method consisting of fractionated irradiation (5.5 Gy x2) followed by intra-bone marrow (IBM) injection of whole bone marrow cells (BMCs) from allogeneic normal C 57 BL/6 (B 6) mice [5.5 Gy X2+ IBM].
Introduction
We have previously shown using various autoimmuneprone mice that conventional allo BMT can be used to prevent and treat a range of autoimmune diseases. 1-3 These findings have recently been confirmed even in humans.4-6 However, in humans, the success rate of BMT across major histocompatibility complex (MHC) barriers is lowered by graft-versus-host disease (GvHD), graft rejection, and incomplete T-cell recovery. Therefore, autologous BMT (auto BMT) or auto peripheral blood stem cell transplantation (PBSCT) is the preferred treatment for autoimmune diseases. There have, however, been reports on the rapid recurrence or persistence of autoimmune diseases after auto BMT or auto PBSCT7 Therefore, it is important to establish a safe new method for allo BMT. 8 We have found that the MRL/lpr mouse, an animal model for autoimmune diseases, is a suitable model for establishing a safe new strategy for all BMT, since the MRL/lpr mouse itself is radio-sensitive (8.5 Gy), while the abnormal hemopoietic stem cells of the MRL/lpr mouse are radio-resistant ( >8.5 Gy); conventional BMT (8.5 Gy plus allo BMT) has a transient effect on autoimmune diseases, which recur 3 months after the BMT. 8
To prevent the recurrence of autoimmune diseases in MRL/lpr mice, we carried out BMT plus bone grafts to replace not only the hemopoietic cells but also the stromal cells with donor cells. This is because there is a MHC restriction between pluripotent hemopoietic stem cells (P-HSCs) and stromal cells. ,11) MRUIpr mice that had been irradiated (8.5 Gy) and then reconstituted with C 57 BL/6 BMCs plus bone grafts survived more than 1
year.11,12
Although we found that allogeneic BMT plus bone grafts (to recruit donor stromal cells) could prevent the development of autoimmune diseases in MRL/lpr mice, this strategy (8.5 Gy/bone/BMT) was found not to be beneficial for the treatment of florid autoimmune diseases in MRL/lpr mice. MRL/lpr mice with small amounts of proteinuria (< +) can endure 8.5 Gy irradiation, whereas MRL/lpr mice with greater degrees of proteinuria (>2+) are more radiosensitive and are unable to withstand 8.5
Gy irradiation due to uremic enterocolitis. We therefore devised a new method, fractionated radiation (5 Gy X2), which reduces acute radiation injury and therefore reduces the side effects of radiation and prevents graft rejection.
Recently, we have found that most donor HSCs are trapped and retained in the liver when they are injected either portal venously (PV) or even intravenously (IV),"
and that the HSCs induce anergy to host CD 8+ T cells."
In addition, we have found a strategy (the PV plus the supplemental IV injections of whole BMCs) that induces persistent tolerance in the skin allograft system. 16 On the basis of these findings, we have very recently established a new strategy for allo BMT: fractionated irradiation (5.5
Gy X2) and the PV plus IV injections of whole BMCs.16
However, this method has two demerits for patients: i) a laparoscope-guided injection of BMCs via the PV is necessary, and ii) an additional IV injection is essential for obtaining a 100% success rate. 16 We have analyzed the mechanism underlying the tolerance induced by the PV injection of BMCs and noted the importance of donorderived stromal cells trapped in the liver, which facilitate the proliferation and differentiation of donor HSCs. Based on these findings, we attempted to inject whole BMCs (including stromal cells) directly into the bone marrow (intra-bone marrow [IBM] injection). We here show that "IBM -BMT" is a powerful strategy for the treatment of intractable autoimmune diseases in chimeric-resistant MRL/lpr mice.
Materials and methods

Mice
Female MRL/Mp-lpr/lpr (MRL/lpr, H-2k), C 57 BL/6 (B 6, H-2b), BALB/c (H-24) were purchased from SLC (Shizuoka, Japan) and maintained until use in our animal facilities under specific pathogen-free conditions.
Preparation of donor BMCs and IBM injection of BMCs
The BMCs were collected from the femurs and tibias of B 6 mice. The IBM injection was carried out as a follow: The region from the inguen to the knee joint was shaved of hairs with a razor. The knee was flexed to 90 degrees and the proximal side of the tibia was drawn to the anterior. A 26-gauge needle was inserted into the joint surface of the tibia through the patellar tendon and then inserted into the bone marrow cavity. Using a microsyringe (50 pl, HAMILTON Co., Reno, NV) containing the donor BMCs (3 X 10 7 /30 y 1) , the donor BMCs were injected from the said bone hole into the bone marrow cavity.
PV injection of BMCs
The BMCs were injected via the PV as described previously.' In brief, a midline incision was made on the abdomen to expose the viscera. The donor BMCs (3X 10 7/0.3 ml) were injected via the superior mesenteric vein using a 27-gauge needle.
Experimental protocols
The onset of autoimmune diseases in MRL/lpr mice was monitored by proteinuria ( > 2.5 +) and lymphadenopathy. The mice (4 to 5 months of age) with autoimmune diseases were irradiated in fractionated doses (5.5 Gy X2=11 Gy; 4-hour interval). One day after the irradiation, the mice were transplanted with the whole BMCs (3X10) by IBM injections [abbreviated as 5.5
GyX2+IBM]. Two groups were prepared as controls.
The first group consisted of mice that were irradiated 
Analyses for donor-derived stromal cells
To prepare the bone marrow-derived stromal cells, the humeri from which the BMCs had been extensively washed out were cut into pieces, and the bone pieces were then cultured in a flask containing PRMI with 10% FBS at 37°C in 5% CO2 in air. Three weeks later, the adherent cells were then collected from the surface of the flask using CELL DISSOCIATION SOLUTION (SIGMA).
To detect donor-derived stromal cells, the cultured cells were stained with anti-PA 6 mAbs, which were reactive to the stromal cells,17 followed by PE-anti-Rat IgG (GIBCO BRL). After blocking with normal rat IgG (PharMingen), the cells were further stained with FITC-anti-H-2 Db or anti-H-2 Kk, and analyzed by a FACScan®. The cultured cells stained with isotype-matched Igs served as a negative control.
Measurement of autoantibodies
RFs (IgG and IgM) and anti-ssDNA Abs (IgG and IgM) in the sera of the recipient mice were determined by a standard enzyme-linked immunosorbent assay (ELISA) as described previously.16
Analyses for immunological functions Antibody production against sheep red blood cells (SRBCs) and mixed leukocyte reaction (MLR) were performed as immunological functions of the treated mice. Anti-SRBC antibody response was evaluated as described previously.16
Statistical analyses
Statistical analyses of the survival rate of the recipient mice were performed using a logrank test.
Proteinuria
Proteinuria was measured using testing papers (Albustix: Miles-Sankyo Ltd Co, Tokyo, Japan).
Results
Survival rates after BMT MRL/lpr mice (4-5 months of age) that had developed the symptoms of autoimmune diseases such as massive lymphadenopathy and proteinuria (more than 2.5+)
were first treated with (5.5 Gy X2+PV). As shown in We reduced the radiation dose from 5.5 Gy X2 to 5 Gy X2 in order to compare the effect of IBM-BMT with that of PV-BMT. MRL/Ipr mice treated with either (5 Gy X2 +PV) or (5 Gy X 2+PV+ IV) showed survival rates of 30% and 50%, respectively ( Figure 1 ). These findings indicate that the 5 Gy X2 irradiation followed by the treatment with PV+ IV is insufficient to prevent graft rejection. In contrast, all the recipients that had received "IBM -BMT" survived 48 weeks after the treatment without showing any signs of graft rejection or recurrence of autoimmune diseases even when treated with 5 GyX2+IBM (Figure 1 ). Furthermore, more than 85% of the MRL/lpr mice survived 30 weeks after the treatment, even when treated with 4.5 GyX2+IBM.
Analyses of donor-derived hemopoietic cells
The percentages of the donor-derived hemopoietic cells and spleen on day 10 ( Fig. 2 B) .
These were histologically confirmed ( Fig. 3 ); both the tibia ( Fig. 3 A) where directly injected with the BMCs, and femur ( Fig. 3 B) , not directory injected with BMCs, showed a remarkable proliferation of hemopoietic cells in comparison with the tibia ( /Lin-cells) could be hardly detected ( Fig. 4 B, dashed line; it is noted that the residual host cells gradually decreased to-0% when treated with [5.5 GyX2+IBM], as shown in Fig. 2 B) . As shown in Fig. 4 A, 14 The glomeruli in the non-treated MRL/lpr mice showed the proliferation of mesangial cells and marked IgG deposits ( Fig. 7 A and 7 B ), whereas the glomeruli in the MRL/lpr mice treated with [5.5 GyX2-FIBM] showed normal appearance without IgG deposits ( Fig. 7 C and 7 D). (Figure 2 and Table 1 ).
Furthermore, the percentages of donor-derived progenitor cells in the bone marrow of both the tibia (BMCs were directly injected) and the femur (BMCs were not injected) significantly increased by 14 days after the treatment (Figure 4) . Therefore, the IBM injection rapidly accelerates the proliferation of donor-derived progenitor cells and simultaneously maintains hemopoietic progenitor cells, resulting in the recovery of hemopoiesis.
In the present study, we have shown that "IBM-BMT" is, so far, the best strategy for allo BMT: i) no GvHD develops even if T cells are not depleted from the bone marrow, ii) no graft failure occurs even if the dose of radiation as the conditioning for BMT is reduced to 5 Gy X2, iii) hemopoietic recovery is rapid, and iv) the restoration of T cell functions is complete even in donorrecipient combinations across the MHC barriers. We believe that this "IBM-BMT" is applicable to humans, since intraosseous (I0) infusion (IBM injection) is now an established method for administering fluids, drugs, and blood to critically ill patients, particularly infants. [40] [41] [42] [43] Indeed, Hagglund et al. have recently compared the effectiveness of 10 infusion with that of IV infusion in human allo BMT;44 they have concluded that allo BMT can be safely performed by 10 infusion, but the incidences of acute and chronic GvHD, transplantationrelated mortality, and survival rates are similar. However, they aspirated the donor BMCs from the iliac bones and infused these BMCs into the iliac bones of the recipients.
Using cynomolgus monkeys, we have just established a new method ("Perfusion Method") for collecting BMCs from the long bones (femur, humerus etc.) without peripheral blood contamination:6.46 This method has various merits: i) no GvHD develops even in cynomolgus monkeys, since the percentage of T cells in the BMCs thus collected is less than 3%, and ii) a large number of BMCs can be collected quickly and safely. We therefore believe that this method ("IBM-BMT') will become a powerful new strategy for not only allo BMT but also organ transplantation in conjunction with BMT. 
